Skip to main content

Table 4 Prevalence of comorbidities among the "most costly" patients compared to the remainder.

From: Determinants of elevated healthcare utilization in patients with COPD

Comorbidity condition (ICD-9 codes) Prevalence   
  "Most costly"* (n = 98) The remainder (n = 291) P value OR 95% CI
Hypertension (401 - 405) 74% 54% <0.001 2.53 1.5 - 4.2
Myocardial infarct (410, 411) 70% 29% <0.001 5.96 3.6 - 9.9
Connective tissue disease (710, 714, 725) 58% 57% 0.89 1.03 0.6 - 1.6
Congestive heart failure (398, 402, 428) 52% 14% <0.001 6.81 4.1 - 11.4
Diabetes Mellitus (250) 50% 24% <0.001 3.10 1.9 - 5.0
Moderate and severe renal disease (403, 404, 580 - 586) 37% 20% 0.001 2.38 1.4 - 3.9
Hemiplegia (342, 434, 436, 437) 29% 13% <0.001 2.66 1.5 - 4.6
Peripheral vascular disease (440 - 447) 24% 13% 0.01 2.09 1.2 - 3.7
Cerebrovascular disease (430 - 433, 435) 23% 12% 0.01 2.17 1.2 - 3.9
Depression/Anxiety (296.2, 296.3, 311) 23% 15% 0.06 1.72 1.0 - 3.0
Peptic ulcer (531 - 534) 22% 15% 0.08 1.67 0.9 - 3.0
Diabetes Mellitus with organ damage (250.4 - 250.7) 21% 9% 0.001 2.78 1.5 - 5.2
Pulmonary hypertension (415, 416) 20% 7% <0.001 3.67 1.9 - 7.2
Any tumor (140 - 195) 17% 10% 0.05 1.90 1.0 - 3.6
Obstructive sleep apnea (780.51, 780.53) 16% 9% 0.06 1.89 1.0 - 3.7
Mild liver disease (571, 573) 8% 3% 0.02 3.14 1.1 - 8.6
Moderate or severe liver disease (070, 570, 572) 7% 2% 0.01 4.40 1.4 - 14.2
Dementia (290, 291, 294) 3% 2% 0.42 1.81 0.4 - 7.7
Lymphoma (200, 202, 203) 1% 0% 0.42 2.99 0.2 - 48.4
Metastatic solid tumor (196 - 199) 1% 2% 0.63 0.59 0.1 - 5.1
Leukemia (204-208) 1% 1% 0.74 1.49 0.1-16.7
  1. None of the patients in this cohort had AIDS.
  2. * The "most costly" patients are those whose annualized utilization cost was within the upper 25 percentile; Chi-square test.